Extract from the Register of European Patents

EP About this file: EP1309692

EP1309692 - ANTI-IL-12 ANTIBODIES, COMPOSITIONS, METHODS AND USES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.03.2010
Database last updated on 07.04.2026
Most recent event   Tooltip19.03.2010No opposition filed within time limitpublished on 21.04.2010  [2010/16]
Applicant(s)For all designated states
Centocor Ortho Biotech Inc.
800/850 Ridgeview Drive
Horsham, PA 19044 / US
[N/P]
Former [2009/24]For all designated states
Centocor Ortho Biotech, Inc.
800/850 Ridgeview Drive
Horsham, PA 19044 / US
Former [2009/20]For all designated states
CENTOCOR, INC.
200 Great Valley Parkway
Malvern, PA 19355 / US
Former [2003/20]For all designated states
Centocor, Inc.
200 Great Valley Parkway
Malvern, PA 19355 / US
Inventor(s)01 / GILES-KOMAR, Jill
31 Blakely Road
Downingtown, PA 19355 / US
02 / KNIGHT, David, M.
2430 Whitehorse Road
Berwyn, PA 19312 / US
03 / PERITT, David
407 Conshohocken State Road
Bala Cynwyd, PA 19004 / US
04 / SCALLON, Bernard
139 Hemlock Drive
Collegeville, PA 19426 / US
05 / SHEALY, David
1351 Penns Ridge Place
Downingtown, PA 19335 / US
 [2003/20]
Representative(s)Mercer, Christopher Paul, et al
Carpmaels & Ransford LLP
One Southampton Row
London
WC1B 5HA / GB
[N/P]
Former [2003/20]Mercer, Christopher Paul, et al
Carpmaels & Ransford 43, Bloomsbury Square
London WC1A 2RA / GB
Application number, filing date01959598.207.08.2001
[2003/20]
WO2001US24720
Priority number, dateUS20000223358P07.08.2000         Original published format: US 223358 P
US20000236827P29.09.2000         Original published format: US 236827 P
US2001092026201.08.2001         Original published format: US 920262
[2003/20]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO0212500
Date:14.02.2002
Language:EN
[2002/07]
Type: A2 Application without search report 
No.:EP1309692
Date:14.05.2003
Language:EN
The application published by WIPO in one of the EPO official languages on 14.02.2002 takes the place of the publication of the European patent application.
[2003/20]
Type: B1 Patent specification 
No.:EP1309692
Date:13.05.2009
Language:EN
[2009/20]
Search report(s)International search report - published on:EP03.01.2003
ClassificationIPC:C12N15/13, C07K16/24, C12N15/79, C12N5/10, A61K39/395, C07K16/42, A61P37/00, G01N33/50, G01N33/577
[2003/20]
CPC:
C07K16/244 (EP,US); C07K16/24 (KR); A61K39/3955 (US);
A61K45/06 (US); A61P1/00 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P21/02 (EP); A61P23/00 (EP);
A61P23/02 (EP); A61P25/00 (EP); A61P25/20 (EP);
A61P25/28 (EP); A61P29/00 (EP); A61P31/00 (EP);
A61P35/00 (EP); A61P37/00 (EP); A61P37/04 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP);
A61P9/00 (EP); A61K2039/505 (EP,US); C07K2317/21 (EP,US);
C07K2317/565 (US); C07K2317/76 (EP,US); C07K2317/92 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2003/20]
Extension statesALNot yet paid
LT06.03.2003
LV06.03.2003
MKNot yet paid
RO06.03.2003
SI06.03.2003
TitleGerman:ANTIKÖRPER GEGEN IL-12, ZUSAMMENSETZUNGEN, VERFAHREN UND VERWENDUNGEN[2003/20]
English:ANTI-IL-12 ANTIBODIES, COMPOSITIONS, METHODS AND USES[2003/20]
French:ANTICORPS, COMPOSITIONS, PROCEDES ANTI-IL-12 ET LEUR UTILISATION[2003/20]
Entry into regional phase06.03.2003National basic fee paid 
06.03.2003Designation fee(s) paid 
06.03.2003Examination fee paid 
Examination procedure07.03.2002Request for preliminary examination filed
International Preliminary Examining Authority: EP
06.03.2003Examination requested  [2003/20]
07.03.2003Amendment by applicant (claims and/or description)
01.02.2006Despatch of a communication from the examining division (Time limit: M06)
01.08.2006Reply to a communication from the examining division
08.02.2008Despatch of a communication from the examining division (Time limit: M06)
08.08.2008Reply to a communication from the examining division
21.11.2008Despatch of a communication from the examining division (Time limit: M02)
29.01.2009Reply to a communication from the examining division
09.03.2009Communication of intention to grant the patent
19.03.2009Fee for grant paid
19.03.2009Fee for publishing/printing paid
Divisional application(s)EP09006396.7  / EP2090657
EP10184116.1  / EP2305817
EP17153336.7  / EP3178934
EP19179253.0
Opposition(s)16.02.2010No opposition filed within time limit [2010/16]
Fees paidRenewal fee
06.03.2003Renewal fee patent year 03
12.08.2004Renewal fee patent year 04
12.08.2005Renewal fee patent year 05
14.08.2006Renewal fee patent year 06
14.08.2007Renewal fee patent year 07
31.03.2008Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X] WO9715327  (US HEALTH et al.) [X] 1-101 * page 5, lines 5-15 * * examples 5,6 *
 [A] WO9633735  (CELL GENESYS INC et al.) [A] 1-101 * page 1, line 31 - page 3, line 30 * * page 15, line 6 *
 [X] WO9937682  (HOFFMANN LA ROCHE et al.) [X] 1-101 * page 2, line 20 - page 3, line 16 * * page 14, lines 15-24 *
 [PX] WO0056772  (BASF AG et al.) [PX] 1-101 * page 2, line 26 - page 5, line 14 * * example 1 *
 [A]   YAWALKAR NIKHIL ET AL: "Expression of interleukin-12 is increased in psoriatic skin.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 111, no. 6, December 1998 (1998-12-01), pages 1053 - 1057, XP008005771, ISSN: 0022-202X [A] 16,36,56,76,96 * abstract *

DOI:   http://dx.doi.org/10.1046/j.1523-1747.1998.00446.x
ExaminationEP0640689
   PADLAN E.A.: "Anatomy of the antibody molecule", MOLECULAR IMMUNOLOGY, vol. 31, no. 3, 1994, pages 169 - 217, XP023620599

DOI:   http://dx.doi.org/10.1016/0161-5890(94)90001-9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.